title: Differential responses to ATPgammaS in the mesenteric and hindlimb vascular bed of the cat.
abstract: The mechanism by which the purinergic agonist adenosine 5'-O-(3 thiotriphosphate) (ATPgammaS) decreases vascular resistance was investigated in the mesenteric and hindlimb vascular beds of the cat. Injections of ATPgammaS into the hindlimb perfusion circuit elicited dose-dependent decreases in perfusion pressure while injections into the mesenteric circuit produced a biphasic response with an initial vasopressor response followed by a vasodepressor response. In the mesenteric vascular bed the pressor response to ATPgammaS was blocked by a P2X1 receptor antagonist. Also an inhibitor of nitric oxide synthase enhanced the vasoconstrictive responses to ATPgammaS. However, the vasodepressor response in the mesenteric bed was not altered by the adminstration of an alpha adrenergic receptor antagonist, a cyclooxygenase inhibitor, a P2Y1 receptor antagonist, or a K+ATP channel blocking agent. These data suggest that the vasopressor response to ATPgammaS in the mesenteric vascular bed of the cat is mediated via P2X1 receptor activation. The differential responses to ATPgammaS in the hindlimb and mesentery suggest differences in purinergic receptor distribution in the vascular system of the cat. In addition, the results suggest that prostaglandin synthesis, P2Y1 receptor activation, alpha receptor inhibition, and K+ATP channels activation play little to no role in mediating the vascular response to ATPgammaS in the mesentery of the cat.
authors.affiliation: Department of Pharmacology, Tulane University School of Medicine, New Orleans, Louisiana 70112, USA. Mrugshah@hotmail.com
authors.forename: M K
authors.initials: MK
authors.lastname: Shah
authors.forename: H C
authors.initials: HC
authors.lastname: Champion
authors.forename: T J
authors.initials: TJ
authors.lastname: Bivalacqua
authors.forename: P J
authors.initials: PJ
authors.lastname: Kadowitz
mesh_terms: D000218:Adamantane / Q000031:analogs & derivatives* / Q000494:pharmacology; D000255:Adenosine Triphosphate / Q000031:analogs & derivatives* / Q000494:pharmacology*; D000818:Animals; D002415:Cats; D005260:Female; D006614:Hindlimb / Q000098:blood supply*; D008297:Male; D008469:Meclofenamic Acid / Q000494:pharmacology; D008643:Mesentery / Q000098:blood supply*; D009025:Morpholines / Q000494:pharmacology; D019331:NG-Nitroarginine Methyl Ester / Q000494:pharmacology; D010646:Phentolamine / Q000494:pharmacology; D058913:Purinergic Agonists; D058914:Purinergic Antagonists; D011732:Pyridoxal Phosphate / Q000031:analogs & derivatives* / Q000494:pharmacology; D014655:Vascular Resistance / Q000187:drug effects*
chemical_list: D009025:Morpholines; D058913:Purinergic Agonists; D058914:Purinergic Antagonists; C077792:pyridoxal phosphate-6-azophenyl-2',4'-disulfonic acid; C022571:adenosine 5'-O-(3-thiotriphosphate); D008469:Meclofenamic Acid; C082658:U 37883A; D011732:Pyridoxal Phosphate; D000255:Adenosine Triphosphate; D000218:Adamantane; D019331:NG-Nitroarginine Methyl Ester; D010646:Phentolamine